Search for: "Sharp v. Merck "
Results 1 - 20
of 201
Sort by Relevance
|
Sort by Date
5 Mar 2024, 10:23 am
Pfizer v. [read post]
3 Jan 2024, 12:08 am
Guest post by Professor Yeo Tiong Min, SC (honoris causa), Yong Pung How Chair Professor of Law, Yong Pung How School of Law, Singapore Management University Merck Sharp & Dohme Corp (formerly known as Merck & Co, Inc) v Merck KGaA (formerly known as E Merck) [2021] 1 SLR 1102, [2021] SGCA 14 (“Merck”), noted previously, is a landmark case in Singapore private international law, being a decision of a full bench of the… [read post]
14 Aug 2023, 5:03 am
(I will have to go away and read Merck Sharp & Dohme Corp v Merck KGaA (2021) 1 SLR 1102 properly.) [read post]
25 Jul 2023, 1:43 am
Merck Sharp & Dohme Corp). [read post]
16 May 2023, 7:33 am
See Merck Sharp & Dohme Corp. v. [read post]
16 May 2023, 7:33 am
See Merck Sharp & Dohme Corp. v. [read post]
16 May 2023, 7:33 am
See Merck Sharp & Dohme Corp. v. [read post]
27 Dec 2022, 4:33 pm
Merck Sharp & Dohme (C-119/22) made by the Finnish Market Court in February 2022 (see here for an English translation of the referring decision) and Merck Sharp & Dohme v. [read post]
5 Oct 2022, 8:12 pm
Merck Sharp & Dohme Corp. [read post]
4 Oct 2022, 11:47 am
Merck Sharp & Dohme Corp., 2022 WL 4541687 (Fed. [read post]
1 Oct 2022, 2:31 pm
Merck Sharp & Dohme Corp., No. [read post]
23 Sep 2022, 9:39 am
selected address issues such as SPC protection for combination products, double patenting, prosecution history estoppel and the influence of declarations made by the patentee in parallel proceedings, the possibility for national courts to request technical opinions from the EPO under Art. 25 EPC, and the disappearance of the cautio iudicatum solvi that was sometimes required from foreign plaintiffs launching (patent) proceedings in Belgium.SPC’s for combination products: still more questions… [read post]
30 Mar 2022, 7:01 pm
The case is noteworthy because it contains a cogent and well-reasoned exploration of many of the issues flowing from the Supreme Court’s decision in Merck Sharp & Dohme Corp. v. [read post]
30 Mar 2022, 4:31 am
Ltd [2022] FCAFC 39 (Ono) and Merck Sharp & Dohme Corp. v Sandoz Pty Ltd [2022] FCAFC 40 (MSD). [read post]
24 Mar 2022, 11:25 am
Supreme Court made a ruling on the federal preemption legal issue in these Fosamax cases in May 2019 (see Merck Sharp & Dohme Corp. v. [read post]
23 Mar 2022, 11:17 pm
Ltd [2022] FCAFC 39 (‘Ono’); and Merck Sharp & Dohme Corp. v Sandoz Pty Ltd [2022] FCAFC 40 (‘MSD’). [read post]
28 Oct 2021, 6:06 am
The importance of proving CGK was highlighted in a recent IP High Court case (Merck Sharp & Dohme Corp. v. [read post]
28 Oct 2021, 6:06 am
The importance of proving CGK was highlighted in a recent IP High Court case (Merck Sharp & Dohme Corp. v. [read post]
17 Oct 2021, 9:24 pm
Ltd v Commissioner of Patents [2021] FCA 643, and Merck Sharp & Dohme Corp. v Sandoz Pty Ltd [2021] FCA 947. [read post]
7 Jul 2021, 11:44 pm
The Commissioner relied on existing Patent Office authority (eg., GD Searle LLC [2008] APO 31), which followed the 2006 decision of a single judge of the Federal Court, Justice Bennett, in Pfizer Corp v Commissioner of Patents (No 2). [read post]
